meperidine (Rx)
Generic: Meperidine
Brand: Demerol, Meperitab
(me- per'i- deen)
Pharmacological Action
Depresses pain impulse transmission at the spinal cord level by interacting with opioid receptors
Therapeutic outcome: Relief of pain
Uses
Moderate to severe pain, preoperatively, postoperatively
Contraindications
Hypersensitivity, severe respiratory insufficiency
Precautions: Pregnancy C, breastfeeding, children, geriatric, addictive personality, increased ICP, respiratory depression, renal/hepatic disease, seizure disorder, abrupt discontinuation, chronic pain, cardiac disease, adrenal insufficiency, alcoholism, angina, anticoagulant therapy, asthma, atrial flutter, biliary tract disease, bladder obstruction, cardiac dysrhythmias, COPD, CNS depression, coagulopathy, constipation, cor pulmonale, dehydration, diarrhea, driving epidural use, geriatrics, GI obstruction, head trauma, heart failure, hypotension, hypothyroidism, ileus, IBS, IM/intrathecal/IV use, labor, myxedema/thrombocytopenia, MAOI therapy
Dosage & Routes
Moderate to severe pain
Adult: PO/SUBCUT/IM 50- 150 mg q3- 4 hr prn
Child: PO/SUBCUT/IM 1- 1.8 mg/kg q3- 4 hr prn, max single dose 150 mg Preoperatively
Adult: IM/SUBCUT 50- 100 mg 30- 90 min before surgery
Child: IM/SUBCUT 1- 2 mg/kg 30- 90 min before surgery, max 100 mg Renal dose
Adult: PO/SUBCUT/IM/IV, CCr 10- 50 ml/min give 75% of dose; CCr < 10 ml/min give 25% 50% of dose Labor analgesia
Adult: SUBCUT/IM 50- 100 mg given when contractions are regularly spaced, repeat q1- 3 hr prn
Available forms: Inj 10, 25, 50, 75, 100 mg/ml; tabs 50, 100 mg; syr 50 mg/5 ml
Implementation - Give with antiemetic if nausea, vomiting occur - Administer when pain is beginning to return; determine dosage interval by patient response; continuous dosing of medication is more effective given prn - Medication should be slowly withdrawn after long-term use to prevent withdrawal symptoms - Store in light-resistant container at room temperature PO route May be given with food or milk to lessen GI upset Syr should be mixed with 4 oz of water Oral liquid: dilute in 4 oz water IM/SUBCUT route Do not give if cloudy or a precipitate has formed Patient should remain recumbent for 1 hr after administration Inject IM into a large muscle mass; IM is preferred route for multiple injections Direct IV route Give after diluting to 10 mg/ml with sterile water, 0.9% NaCl for inj; give slowly at ≤ 25 mg/min; rapid administration may cause respiratory depression, hypotension, circulatory collapse Have emergency equipment and opiate antagonist on hand Continuous IV infusion route Give after diluting to 1 mg/ml with D₅W D₁₀W dextrose/saline combinations, dextrose/Ringer's, inj combinations, 0.45% NaCl, 0.9% NaCl, Ringer's, LR; give by inf pump; titrate according to response
Syringe compatibilities: Butorphanol, chlorproMAZINE, cimetidine, dimenhyDRINATE, diphenhydRAMEINE, droperidol, fentaNYL, glycopyrrolate, hydROXYzine, ketamine, metoclopramide, midazolam, pentazocine, perphenazine, prochlorperazine, promazine, ranitidine, scopolamine Syringe incompatibilities: Heparin, morphine, PENTobarbital
Y- site compatibilities: Amifostine, amikacin, atenolol, aztreonam, bumetanide, cefamandole, ceFAZolin, cefmetazole, cefotaxime, cefOXitin, cefTAZidime, ceftizoxime, cefTRIAXone, cefuroxime, cladribine, clindamycin, diltiazem, diphenhydRAMEINE, DOBUTamine, DOPamine, doxycycline, droperidol, erythromycin lactobionate, famotidine, filgrastim, fluconazole, fludarabine, gallium, gentamicin, granisetron, hydrocortisone, regular insulin, kanamycin, labetalol, lidocaine, melphalan, methylodopate, metoclopramide, metoprolol, metroNIDAZOLE, ondansetron, oxytocin, PACLITaxel, penicillin G potassium, piperacillin, potassium chloride, propofol, propranolol, ranitidine, sargramostim, teniposide, thiotepa, ticarcillin, ticarcillin/clavulanate, tobramycin, vancomycin, verapamil, vinorelbine Y- site incompatibilities: Cefoperazone, IDArubicin, imipenem/cilastatin, mezlocillin, minocycline Continuous intrathecal infusion route Use controlled- infusion device, an implantable controlled- microinfusion device is used for highly concentrated infusion, monitor for several days after implantation Infusion reservoir should only be filled by those fully qualified To prevent pain, depletion of reservoir should be avoided
Adverse Effects
CNS: Drowsiness, dizziness, confusion, headache, sedation, euphoria, increased ICP, seizures, serotonin syndrome
CV: Palpitations, bradycardia, hypotension, change in B/P, tachycardia (IV)
EENT: Tinnitus, blurred vision, miosis, diplopia, depressed corneal reflex
GI: Nausea, vomiting, anorexia, constipation, cramps, biliary spasms, paralytic ileus
GU: Urinary retention, dysuria
INTEG: Rash, urticaria, bruising, flushing, diaphoresis, pruritus
RESP: Respiratory depression
SYST: Anaphylaxis
Pharmacokinetics
Absorption: Well absorbed (IM, SUBCUT); 50% (PO)
Distribution: Widely distributed; crosses placenta; protein binding 65%-75%; toxic by- product accumulation can result from regular use or in renal disease
Metabolism: Liver, extensively to active/inactive metabolites
Excretion: Kidneys; breast milk Half- life: 3-4 hr
Pharmacodynamics
PO: Onset 15 min, Peak 1-1½ hr, Duration 2-4 hr
IM/SUBCUT: Onset 10 min, Peak ½-1 hr, Duration 2-4 hr
IV: Onset 5 min, Peak 5-7 min, Duration 2 hr
Interactions
Individual drugs
Alcohol: increased respiratory depression, hypotension, sedation
Phenytoin: decreased meperidine effect
Procarbazine: fatal reaction, do not use together
Drug classifications CNS depressants, opioids, sedative/hypnotics, antipsychotics, skeletal muscle relaxants: increased effects SSRIs, SNRIs, serotonin- receptor agonists: increased serotonin syndrome, increased neuroleptic malignant syndrome
MAOIs: do not use for 2 wk before taking meperidine; may cause fatal reaction Protease inhibitor antiretrovirals: increased adverse reactions
Drug/herb St. John's wort: increased CNS depression
Drug/lab test
Increased: amylase, lipase
Nursing Considerations
Assessment - Assess pain: location, duration, intensity before and 1 hr (IM, SUBCUT, PO), 5- 10 min (IV) after administration - Assess renal function before initiating therapy; poor renal function can lead to accumulation of toxic metabolite and seizures - Monitor VS after parenteral route; note muscle rigidity, product history, liver, kidney function tests, respiratory dysfunction: respiratory depression, character, rate, rhythm; notify prescriber if respirations are < 10/min - Monitor CNS changes: dizziness, drowsiness, hallucinations, euphoria, LOC, pupil reaction; these are due to metabolite produced; CNS stimulation occurs with chronic or high doses - Monitor allergic reactions: rash, urticaria - Assess for constipation; increase fluids, bulk in diet; give stimulant laxatives if needed
Patient/family education - Advise patients to avoid CNS depressants (alcohol, sedative/hypnotics) for at least 24 hr after taking this product - Discuss with patient that dizziness, drowsiness, and confusion are common; to avoid getting up without assistance - Discuss in detail with patient all aspects of the product, including its purpose and what to expect - Caution patient to make position changes carefully to lessen orthostatic hypotension
Evaluation - Decreased pain TREATMENT OF
OVERDOSE: Naloxone 0.2- 0.8 mg IV (caution in physically dependent patients), O₂, IV fluids, vasopressors
Reference
Need clinical tools for this drug?
Save notes, bookmark this drug, and run formula method (desire over have) dosage calculations all inside the KosPharm Dashboard.
One-time payment. No subscription. No recurring charges.
Sign in to Get Full Access